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The pathways underlying chronic obstructive pulmonary disease exacerbations (ECOPD) remain
unclear. This study describes the clinical, functional and biochemical changes during recovery
from ECOPD.
Thirty hospitalized patients with Anthonisen’s type-I ECOPD were evaluated on days
0 (admission), 3, 10 and 40. A five-symptom score (TSS), performance status and quality of life
were evaluated. Post-bronchodilator spirometry, blood gases, oxidative stress, C-reactive
protein (CRP), serum amyloid-A (SAA), tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6)
and fibrinogen were also measured. Patients were classified as early- or late-recoverers, based
on whether dyspnea had returned to pre-exacerbation level by day 10.
Most clinical, functional and biochemical parameters improved during follow-up. CRP and IL-
6 levels reduced on Day 3 (p< 0.05), whereas SAA on Day 10 (p< 0.01). TNF-a was reduced on
Days 3 and 10, but on Day 40 its levels returned to baseline. Fibrinogen and WBC reduced only
by day 40. TSS and dyspnea were correlated inversely with FEV1 on days 3, 10 and 40. Althoughoracic Society/European Respiratory Society; BMI, body mass index; CBC, complete blood count;
disease; CRP, C-reactive protein; ECOPD, exacerbations of chronic obstructive pulmonary disease;
; FEV1, forced expiratory volume in 1 s; FiO2, fraction of inspired oxygen; FVC, forced vital capacity;
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920 A. Koutsokera et al.late-recoverers had lower FEV1 on admission, none of the reported measurements on admis-
sion and day 3 predicted early recovery.
During recovery from ECOPD, symptomatic improvement correlates only with post-
bronchodilator FEV1 whereas systemic inflammatory burden subsidence does not correlate
with clinical and functional changes. Although late-recoverers have lower FEV1 on admission,
none of the measured parameters is able to predict early symptomatic recovery.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Patients with chronic obstructive pulmonary disease (COPD)
are prone to recurrent episodes of deterioration, called
exacerbations of COPD (ECOPD). Although these events
represent a significant burden on patient welfare and on
healthcare resources, their heterogeneity renders difficult
the establishment of a standardized definition.1 Currently,
COPD exacerbations are diagnosed on clinical grounds,
when specific symptoms deteriorate beyond day-to-day
variability, whereas severity is rated according to health-
care resource utilization.2
There is also evidence that ECOPD affect the natural
history of COPD and accelerate disease progression.3 Thus,
improving patient outcomes vastly depends on our under-
standing of the pathophysiology of ECOPD and on our ability
to modify it. So far, only a limited number of studies have
focused on the functional4,5 and inflammatory changes5e8
which occur during the course of ECOPD. Revealing the
complex interactions between clinical, functional and
inflammatory changes represents a challenging task, since
the underlying pathways of ECOPD still remain unclear.
The aim of this study was to evaluate prospectively the
alterations of clinical, functional and biochemical param-
eters in a homogeneous population of hospitalized patients
with Anthonisen’s type-I ECOPD, in an effort to describe the
changes that accompany recovery from exacerbation.
Additionally, we tested the hypothesis that, during the
course of ECOPD, the improvement of functional and
biochemical variables may reflect the amelioration of
symptoms as perceived by the patients. We also investi-
gated whether clinical parameters correlate with the
changes of functional parameters or biomarkers. Finally,
we attempted to determine predictors of early recovery.
Methods
Study subjects
Details on methodology are available in the supplementary
material. Study participants presented with Anthonisen’s
type-I9,10 and ATS/ERS level-II ECOPD,2 aged more than 50
years and had a smoking history of at least 20 pack-years.
All patients were evaluated within 72 h of the onset of
symptomatic deterioration and they were included into the
study if the respiratory physician in charge, who was not an
investigator, decided hospitalization according to the GOLD
criteria.11 The study protocol was approved by the local
Ethical Committee and all participants gave written
informed consent.Exclusion criteria were the following: respiratory failure
requiring mechanical ventilation; hemodynamic instability;
another acute condition; other chronic respiratory disor-
ders; use of systemic corticosteroids or antibiotics during
the previous month; multiple comorbidities; and inability to
cooperate with investigations. Patients were dropped-out if
any of the following adverse outcomes occurred during
follow-up: death, initiation of mechanical ventilation or
recurrent ECOPD.
Study design
Patients were evaluated on days 0 (admission), 3, 10 and 40.
On admission, medical history, use of medication, clinical
findings, Charlson’s Comorbidity Index Score (CCIS)12,13 and
Mini Nutritional Assessment (MNA) were recorded.14
Treatment was in accordance to recently published
guidelines,2 including inhaled b2-agonists and anticholiner-
gics, methylprednisolone (60 mg IV bid during hospitalization
followed by oral methylprednisolone for a total of 10e14
days) and antibiotics (IV during hospitalization followed by
an oral course for a total of 10e14 days). Oxygen was
provided in order to maintain SatO2 90%.
Clinical assessment
Vital signs, Karnofsky’s performance status and a total
symptom score (TSS) were recorded. TSS derived from the
sum of five symptoms (dyspnea, cough, sputum production,
wheezing and night-time awakenings), each of which was
assessed with a modified Borg scale (supplementary Table 1).
Quality of life was evaluated, on days 0 and 40, with the St.
George’s Respiratory Questionnaire (SGRQ).
On days 3, 10 and 40, patients were asked if the severity
of their dyspnea had returned to pre-exacerbation level;
patients reporting recovery of dyspnea by day 10 were
classified as ‘‘early-recoverers’’, otherwise they were
classified as ‘‘late-recoverers’’.
Functional assessment
Post-bronchodilator spirometry was conducted with a dry
spirometer (KoKo Legend, Ferraris, UK), according to
previously published guidelines. Arterial blood gas
measurements were also performed.
Assessment of biomarkers
Blood samples, including complete blood counts, were
obtained on each assessment day. Serum and plasma were
Recovery from COPD exacerbations 921processed by two investigators (T.S.K., D.J.N.) who were
unaware of the subjects’ clinical features. Oxidative stress
was measured with a commercially available spectropho-
tometric method (d-ROMs test; Diacron, Grosseto, Italy;
described in the supplementary material) used to assess
overall reactive oxygen metabolites expressed in conven-
tional units (UCarr; 1 UCarr corresponds to 0.8 mg/L
H2O2).
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Serum and plasma samples were stored at 80 C for
a subsequent measurement of C-reactive protein (CRP),
serum amyloid-A (SAA), interleukin-6 (IL-6), tumor necrosis
factor-alpha (TNF-a) and plasma fibrinogen. CRP, SAA and
fibrinogen were quantified by immunonephelometry
(Behring Nephelometer Analyzer-II) with the N-High Sensi-
tivity kit, a latex-enhanced assay and the N-antiserum to
human fibrinogen, respectively. Appropriate controls and
standard sera were provided by the same company (Dade
Behring, Inc., Germany). IL-6 and TNF-a levels were
measured in serum with a commercially available enzyme-
immunosorbent assay (Biosource Europe S.A.).
Statistical analysis
Data are presented as mean (SEM). Comparisons between
two groups were performed with unpaired t-tests.
Repeated measures one-way analysis of variance (ANOVA)
with Bonferroni post hoc correction was used to analyze the
time-course of variables. Pearson’s correlation coefficient
was utilized to determine correlations between different
parameters. Normality of distribution was examined with
KolmogoroveSmirnov test. Statistical significance was
defined as p-values< 0.05.
Binary logistic regression was used in order to identify
predictors of early recovery,16 using recovery by day 10 as
the dependent variable, and TSS, respiratory rate, FEV1,
PaO2/FiO2, WBC, serum oxidative stress, CRP, SAA, TNF-a,Figure 1 Flow chart diagram of study participaIL-6 and fibrinogen on admission, on day 3 and their
difference between admission and day 3 as covariates.
Analysis was performed with SPSS 13.0 and graphs were
drawn with SigmaPlot 8.0.
Results
The flow chart of the evaluated subjects is presented in
Fig. 1. Thirty-five (40%) of the 87 hospitalized patients who
were initially evaluated, participated in the study, whereas
5 of them were subsequently dropped-out due to adverse
outcomes. Baseline characteristics of the 30 patients who
were included in the study are presented in Table 1. The
majority of the subjects were well-nourished as demon-
strated by the MNA and the BMI and did not present major
comorbidities, as confirmed by Charlson’s score.
Mean length of hospitalization was 6 (0.3) days, but
patients were followed for a time period of 40 days, during
which they all presented symptomatic recovery. Two
patients (belonging to the late recovery group) were unable
to perform spirometry at admission due to dyspnea
severity, whereas two subjects were missed during the final
visit (had already reported early symptomatic recovery)
and were contacted by phone to ascertain that an adverse
outcome had not occurred. This limited loss of data should
not detract from the relevance of this study. The course of
the clinical, physiological and biochemical parameters for
the whole group of patients is presented in Table 2 and
Fig. 2.
Clinical parameters
The total symptom score (TSS) and its individual compo-
nents presented a statistically significant improvement on
Day 3. TSS ameliorated further on Day 10. Despite the factnts and reasons for exclusion from the study.
Table 1 Baseline characteristics of the subjects who were included in the study and comparisons between early and late-
recoverers.
Parameter All patients Early-recoverers Late-recoverers p-Value
Patients, n (%) 30 (100%) 14 (47%) 16 (53%)
Age, yrs 69.3 (1.7) 69.2 (2.8) 69.4 (2.3) 0.952
Gender (female/male), n 2/28 0/14 2/14




BMI, kg/m2 25.7 (1.0) 25.8 (1.3) 25.6 (1.5) 0.917
Charlson’s Comorbidity
Index Score (CCIS)
1.9 (0.2) 2.0 (0.2) 1.6 (0.2) 0.424
MNA score 23.0 (0.7) 23.9 (0.6) 22.4 (1.2) 0.302
Well-nourished, n (%) 18 (60%) 8 (57%) 10 (62.5%)
At risk for malnutrition, n (%) 10 (33.3%) 6 (43%) 4 (25%)
Malnourished, n (%) 2 (6.7%) 0 (0%) 2 (12.5%)
Pre-exacerbation use of medication, n (%)
Bronchodilators 30 (100%) 14 (100%) 16 (100%)
Inhaled corticosteroids 30 (100%) 14 (100%) 16 (100%)
Systemic corticosteroids 0 (0%) 0 (0%) 0 (0%)
Long-term oxygen therapy 14 (47%) 6 (43%) 8 (50%)
Presented data were normally distributed and are expressed as mean (SEM), unless otherwise stated. COPD was not included in the
calculation of Charlson’s comorbidity index score.
Abbreviations: BMI, body mass index; and MNA, mini nutritional assessment.
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reduced within the first three days of therapy administra-
tion, performance status improvement was observed on
Day 10. Quality of life also improved by Day 40.
Functional parameters
Forced expiratory volume in 1 s (FEV1) and forced vital
capacity (FVC) improved on Day 10 and this improvement
persisted until Day 40. A similar pattern was observed for
PaO2/FiO2.
Serum and plasma biomarkers
CRP, IL-6, and SAA were the biomarkers that presented
more rapid improvement. In particular, CRP and IL-6 were
significantly reduced within the first 3 days (p< 0.05 for
both), whereas SAA was reduced on Day 10 (p< 0.01).
Interestingly, TNF-a levels were reduced on Days 3 and 10,
but on Day 40 they did not differ significantly from baseline,
presenting a trend for increase after the initial reduction.
White blood cell count and fibrinogen were reduced
significantly only by day 40. Serum oxidative stress levels
did not differ throughout the course of ECOPD.
Correlations
TSS and FEV1 correlated inversely on days 3 (pZ 0.002,
rZ0.68), 10 (pZ 0.006, rZ0.60) and 40 (pZ 0.005,
rZ0.70). In a similar pattern, dyspnea presented an
inverse correlation with FEV1 (for day 3 pZ 0.003,
rZ0.67; for day 10 pZ 0.0005, rZ0.72; and for day
40 pZ 0.0007, rZ0.79). No other significant correlationswere observed between measured parameters and their
changes (D), throughout the study period.
Patients with early and late recovery
Baseline demographic characteristics did not differ neither
between early and late-recoverers (Table 1) nor between the
5 patients who presented adverse outcomes and the 30
patients who completed the study. Although none of the
patients reported recovery by day 3, 14 (47%) subjects
reported that their symptoms had returned to the pre-
exacerbation level by day 10 (early-recoverers), whereas 16
(53%) reported recovery from exacerbation symptoms by day
40 (late-recoverers). The baseline clinical and biochemical
parameters were similar between the two subgroups, but the
late-recoverers had lower baseline FEV1 compared to the
early-recoverers [32.2 (3.2) % vs. 47.1 (5.9) % respectively,
pZ 0.028]. However, FEV1 values on Day 40 did not differ
significantly between the two subgroups [41.8 (4.0) % vs. 48.3
(6.1) % respectively, pZ 0.4]. The baseline clinical,
biochemical and functional parameters of the 5 patients who
presented adverse outcomes and were subsequently drop-
ped-out did not differ significantly from the corresponding
values of the late-recoverers’ group.
Change (D) of measured parameters
The change of the total symptom score (DTSS) between
days 0 and 10 was greater in the early-recoverers compared
to the late-recoverers [25.7 (3.7) vs. 14.9 (2.5) respec-
tively, pZ 0.022]. The differences (D) of the functional and
biochemical markers between all possible pairs of the
assessment days did not differ significantly between the
two subgroups of patients.
Table 2 Alterations of clinical, functional and biochemical parameters during the course of COPD exacerbations for the whole
group of patients.
Parameters Day 0 Day 3 Day 10 Day 40
Clinical
Symptoms Dyspnea 7.7 (0.3) 5.6 (0.6)* 4.5 (0.6)z 3.7 (0.6)z
Cough 5.3 (0.5) 2.9 (0.3)z 2.4 (0.2)z 1.5 (0.3)z
Wheezing 4.5 (0.6) 1.7 (0.5)z 0.9 (0.3)z 0.3 (0.1)z
Sputum 5.6 (0.6) 2.9 (0.4)y 1.5 (0.3)z 0.8 (0.3)z,yx
Night awakening 5.4 (0.8) 1.4 (0.5)z 0.5 (0.4)z 0.0 (0.0)z
TSS 29.4 (1.7) 14.5 (1.4)z 9.8 (1.2)z,*x 6.3 (0.8)z, zx
SGRQ Total score 69.0 (2.3) N/A N/A 47.5 (5.3)z
Performance status Karnofsky scale 65.5 (2.6) 66.8 (3.2) 73.2 (3.3)y,*x 80.0 (3.0)z,zx
Physical examination Respiratory rate, breaths/min 26.0 (1.0) 21.5 (0.8)z 18.2 (0.7)z,zx 17.1 (0.5)z,zx
Heart rate, beats/min 84.0 (2.3) 78.8 (2.7) 80.3 (2.3) 77.4 (2.9)
Functional
Spirometry FEV1, % 38.6 (3.5) 38.2 (3.5) 40.3 (3.9)* 44.6 (4.6)
z,*x
FVC, % 57.9 (3.3) 60.8 (4.1) 63.7 (4.4)z 66.2 (4.3)z
FEV1/FVC 51.3 (3.0) 48.8 (2.4) 49.0 (2.3) 51.6 (3.2)*
x
FEF25e75%, % 17.0 (2.0) 16.2 (2.2) 17.3 (2.4) 20.1 (3.0)*
Arterial blood gases pH 7.44 (0.01) 7.44 (0.01) 7.44 (0.01) 7.45 (0.01)
PaO2/FiO2 285.4 (11.9) 300.3 (14.6) 322.5 (15.8)
y 336.1 (16.1)y
PaCO2, mmHg 40.3 (1.9) 42.4 (1.9) 42.2 (1.7) 40.5 (1.3)
Biochemical
CBC WBC, cells/ml 10,658 (809) 8326 (513) 9105 (778) 7186 (419)y
Neutrophils, cells/ml 7337 (829) 5774 (511) 6316 (659) 4615 (385)
Lymphocytes, cells/ml 1721 (197) 1653 (135) 1800 (166) 1815 (158)
Serum Oxidative stress, UCarr 456.1 (25.2) 468.8 (25.5) 457.7 (26.5) 485.6 (27.9)
CRP, mg/dl 5.4 (1.2) 2.6 (0.6)* 0.9 (0.2)z 0.9 (0.2)z
SAA, mg/dl 25.5 (9.2) 10.3 (3.8) 1.8 (0.5)y 1.4 (0.4)z
IL-6, pg/ml 36.3 (10.2) 14.5 (3.9)* 14.1 (3.2)* 11.5 (2.5)*
TNF-a, pg/ml 60.8 (13.0) 37.4 (6.4)z 38.8 (6.6)* 51.2 (11.2)
Plasma Fibrinogen, mg/dl 545.1 (35.9) 564.6 (45.6) 476.4 (34.2) 455.4 (30.0)*x
Data were normally distributed and are presented as mean (SEM): *p< 0.05; yp< 0.01; and zp< 0.001. When only the aforementioned
symbols are used a particular day is compared to Day 0, whereas x signifies comparison of the current day with Day 3.
Abbreviations: N/A, not assessed; TSS, total symptom score; SGRQ, Saint George’s Respiratory Questionnaire; FEV1, forced expiratory
volume in one second; FVC, forced vital capacity; FEF25e75%, forced mid-expiratory flow; PaO2, partial arterial oxygen tension; PaCO2,
partial arterial carbon dioxide tension; FiO2, fraction of inspired oxygen; CBC, complete blood count; WBC, white blood cells; CRP,
C-reactive protein; SAA, serum amyloid-A; IL-6, interleukin-6; and TNF-a, tumor necrosis factor-alpha.
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Binary logistic regression analysis failed to identify signifi-
cant predictors of early symptomatic recovery among study
parameters.
Discussion
The principal findings of this study are summarized in the
following points: (1) during recovery from ECOPD, symp-
tomatic improvement correlates only with FEV1 ameliora-
tion; (2) systemic inflammatory burden subsidence does not
correlate with parameters of clinical or functional
improvement; and (3) although late-recoverers have lower
FEV1 on admission, none of the measured parameters is
able to predict early symptomatic recovery. This study
extends previously conducted research by describing in
parallel the sequence of several clinical, functional and
biochemical events that occur during the course of Antho-
nisen’s type-I COPD exacerbations, from the time of their
burst to their symptomatic resolution, in an attempt to
outline the natural history of ECOPD.There is limited information available on the changes of
symptom perception during the course of ECOPD and on
how recovery is translated into health status improvement.
As far as the symptoms are concerned, previously con-
ducted studies have focused on dyspnea alone and have
demonstrated a decrease in its severity, which occurs
within 48 h after therapy initiation. In the current study, we
evaluated five symptoms and combined them into one
score, in an effort to obtain an overall view of the patients’
perceived symptoms. Individual symptom quantification
was done with the modified Borg scale, an assessment tool
that can be rapidly used in the critical care setting and is
able to detect small changes during serial measurements.
In accordance to previous studies,4,5 dyspnea severity
declined rapidly, as did the TSS. Although TSS provided
a more detailed perspective, dyspnea alone was equally
helpful in patient evaluation. Additionally, despite the
relatively rapid improvement of symptom perception,
performance status ameliorated after the 10th day,
improving further within the next month, and quality of life
improved by day 40. Moreover, FEV1 was the only
Figure 2 Changes of the measured parameters during the course of ECOPD, from the time of admission and during the follow-up
period, presented as mean (SEM): (a) change of total symptom score (TSS) and FEV1; (b) change of serum amyloid-A (SAA) and C-
reactive protein (CRP); (c) change of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-a); and (d) change of white blood
cells (WBC) and plasma fibrinogen. *: p< 0.05; y: p< 0.01; and z: p< 0.001 when only the aforementioned symbols are used
a particular day is compared to Day 0, whereas x signifies comparison of the current day with Day 3.
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quantifying objectively the symptoms that were subjec-
tively described by the patients. This correlation provides
evidence of the valuable role of spirometry in the clinical
assessment and the follow-up of ECOPD patients.
In the present study, pre-exacerbation pulmonary
function tests were not available for all patients.
However, at hospital admission or even during follow-up,
clinicians are rarely able to view pre-exacerbation
spirometry reports. Despite this limitation, in everyday
clinical practice, symptom deterioration as perceived by
the patients and clinical signs as recognized by the
physicians lead to the decisions for treatment and hospi-
talization. In the current study, spirometry on admission
and on day 40 revealed a moderate to severe airway
obstruction for the whole group of patients. FEV1 and FVC
improvement observed after the 10th day is in agreement
with the findings of Parker and colleagues,4 although we
also noted a modest amelioration of FEV1/FVC during the
last days of the follow-up period. The parallel course ofsymptomatic recovery and FEV1 is demonstrated by their
correlation during follow-up. On admission, however, this
was not obvious, a fact that could be attributed to the
unanticipated influence of psychological and environ-
mental factors on symptom perception, in the critical care
setting.17
Although the microbiological confirmation of the cause
of the exacerbations was not part of our investigations, all
patients had purulent sputum, in accordance to the defi-
nition of Anthonisen’s type-I exacerbations. Previously
conducted studies have demonstrated that purulent
sputum in ECOPD is invariably associated with a large
bacterial load and a significant bronchial and systemic
inflammatory burden.6,18,19 In the present study, the
selection of specific biomarkers was based on previous
publications concerning serum, plasma, sputum or BAL
during ECOPD as compared to stable COPD.6,20e23 Addi-
tionally, SAA has just recently been described as
a biomarker in the context of ECOPD24 but previously con-
ducted studies in cystic fibrosis patients with lung infection
Recovery from COPD exacerbations 925had demonstrated that its levels paralleled the clinical
response to treatment.25
It has been shown that systemic inflammation assessed
by CRP subsides during symptomatic recovery, whereas
heightened systemic inflammation is associated with
recurrent exacerbations.8 In accordance with previous
observations, CRP levels declined during recovery and SAA,
although not previously assessed serially in ECOPD, had
a time-course similar to that of CRP. Thus, the changes of
CRP and SAA, although not correlating with the clinical or
functional parameters, paralleled with the clinical
response to treatment indicating that they both could be
used as markers of uneventful recovery. On the other hand,
systemic oxidative stress, assessed with the D-ROMs test,
did not change significantly during follow-up and may not
represent a useful marker for monitoring recovery from
ECOPD.
Previous studies suggested that acute fibrinogen eleva-
tion might increase the susceptibility of COPD patients to
ischemic events.20,26 Although ECOPD are associated with
increased fibrinogen levels, serial measurements of this
biomarker during recovery have not been conducted yet.20
In the current study, we observed that the relatively stable
levels of fibrinogen during the first day of the follow-up
were followed by a modest decline almost one month after
the initial deterioration. Although lack of pre-exacerbation
fibrinogen levels limits definite conclusions, this pattern of
changes might partly explain the elevated risk for cardio-
vascular events during the early recovery period.27
IL-6 plays a crucial proinflammatory role by stimulating
the production of most acute-phase proteins, whereas TNF-
a possesses several complex immunoregulatory properties
and it has been implicated in the development of cachexia.
In accordance with previous studies, IL-6 levels subsided
rapidly during follow-up.5,7,8 However, TNF-a followed
a rather distinctive pattern (it subsided by the 3rd day and
rose again towards admission values during the next month)
providing evidence of a sustained inflammatory reaction
during the late recovery period which may preclude full
recovery and predispose patients with frequent exacerba-
tions to worse outcomes.
Clinical and inflammatory changes occurring during
ECOPD have been the subject of a recent study by Pinto-
Plata and colleagues,5 reporting that in ECOPD patients
FEV1, dyspnea and plasma IL-6 decreased during hospi-
talization, whereas plasma TNF-a levels did not change
significantly. Although no correlations were directly
observed among measured variables, inverse correlations
were found between FEV1, IL-6 and TNF-a changes (D).
The inclusion of both Anthonisen’s type-I and II ECOPD in
the study of Pinto-Plata and the quantification of plasma
cytokines may account for the differences with our
results.
According to Spencer and co-workers, recovery from an
infectious exacerbation may be divided into two phases:
a rapid improvement phase during the first 4 weeks and
a slower improvement phase lasting several months.28 Our
study design required that patients would be followed-up
for 40 days during which it was expected that most of them
would respond to treatment and would be able to report
symptomatic recovery, provided that a recurrent ECOPD
would not occur. In the study of Parker et al. it wasobserved that 60% (12 out of 20) of patients reported
recovery by day 60,4 whereas Seemungal and co-workers
found that 14% of patients failed to reach symptomatic
recovery by day 35.29 In the current study 30 of 35 patients
(85%) recovered by day 40.
As already mentioned patients with ECOPD presenting to
healthcare professionals form a heterogeneous population.
In this study, we included participants who would form
a well-defined group of subjects (i.e. Anthonisen’s type-I
and ATS/ERS level-II ECOPD) and excluded level-I and III
exacerbations exactly because it was required that serial
measurements should be conducted within a short-time
interval by patients who would be able to cooperate with
investigators. Additionally, study participants did not suffer
from comorbidities which could influence the measured
parameters. However, we cannot exclude the possibility
that the course of the studied parameters was influenced
by treatment.4,30 Although corticosteroids were adminis-
tered according to published guidelines, they may be
partially responsible for the observed changes, due to their
immunosuppressive properties.
We have shown that approximately half of the hospi-
talized subjects with Anthonisen’s type-I ECOPD experience
a more rapid improvement of their symptoms, whereas for
the rest improvement is observed during the last 30 days of
the follow-up. Those subgroups shared similar baseline
characteristics, and although they did not differ as far as
systemic inflammation was concerned, the late-recoverers
had lower FEV1 on admission (it is noteworthy however that
FEV1 values on Day 40 did not differ significantly between
the two subgroups). In the study of Parker and co-workers,
it was demonstrated that non-recovered ECOPD patients
fail to improve FEV1 during the follow-up period.
4 These
findings combined suggest that spirometry may provide
useful information for the follow-up and outcome of these
patients. However, in our study none of the parameters
that were measured on admission or day 3 were significant
predictors of early symptomatic recovery. This probably
reflects the complex multifactorial nature of ECOPD and
delineates the significance of follow-up assessment.
In conclusion, we have shown that during recovery from
ECOPD, symptomatic improvement (and particularly dysp-
nea decline) correlates only with FEV1 amelioration,
whereas systemic inflammatory burden subsidence does not
correlate with parameters of clinical or functional
improvement. Although, early symptomatic recovery
cannot be predicted based on single time-point assess-
ments, follow-up measurements may assure uneventful
recovery. In this context, it has been shown that simple
spirometry is feasible in the majority of hospitalized
patients with ECOPD and may provide useful information
for the follow-up and outcome of these patients, whereas
changing patterns of certain biomarkers (especially CRP,
SAA, TNF-a, IL-6 and fibrinogen) may provide an insight into
the underlying pathways of ECOPD and their impact on the
natural history of COPD itself.Conflict of interest statement
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